Methyl 2-Oxoindoline-6-Carboxylate CAS 14192-26-8 Tsarkake>99.0% (HPLC) Nintedanib Esylate Intermediate Factory
Shanghai Ruifu Chemical Co., Ltd. shine babban masana'anta kuma mai ba da kayayyaki na Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) tare da babban inganci, samar da kasuwanci.
Sunan Sinadari | Methyl 2-Oxoindoline-6-Carboxylate |
Makamantu | 2-Oxoindoline-6-Carboxylic Acid Methyl Ester;Methyl Oxindole-6-Carboxylate |
Lambar CAS | 14192-26-8 |
Lambar CAT | Saukewa: RF-PI1524 |
Matsayin Hannun jari | A cikin Hannun jari, Ma'aunin samarwa Har zuwa Ton |
Tsarin kwayoyin halitta | Saukewa: C10H9NO3 |
Nauyin Kwayoyin Halitta | 191.19 |
Matsayin narkewa | 184.0 ~ 190.0 ℃ |
Alamar | Ruifu Chemical |
Abu | Ƙayyadaddun bayanai |
Bayyanar | Rawaya Mai Haske zuwa Foda Brown |
1 H NMR Spectrum | Daidaita Da Tsarin |
Tsarkake / Hanyar Bincike | > 99.0% (HPLC) |
Asara akan bushewa | <1.00% |
Jimlar ƙazanta | <1.00% |
Matsayin Gwaji | Matsayin Kasuwanci |
Amfani | Matsakaicin Nintedanib Esylate (CAS: 656247-18-6) |
Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) Hanyar roba
Kunshin: Bottle, Aluminum tsare jakar, 25kg / Kwali Drum, ko bisa ga abokin ciniki ta bukata.
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi.
Methyl 2-Oxoindoline-6-Carboxylate (CAS: 14192-26-8) matsakaici ne da ake amfani dashi don shirya Nintedanib Esylate (CAS: 656247-18-6).Nintedanib Esylate mai ƙarfi ne, mai hanawa na baka sau uku angiokinase wanda Boehringer Ingelheim ya haɓaka wanda ke yin niyya ta hanyoyin proangiogenic da pro-fibrotic waɗanda ke shiga tsakani ta hanyar mai karɓar haɓakar haɓakar jijiyar jijiyoyi, mai karɓar haɓakar haɓakar fibroblast da plateletderived girma factor iyalai, kazalika da Src da Flt-3 kinase.An amince da Nintedanib Esylate don maganin fibrosis na huhu na huhu (IPF), yanayin da huhu ke ci gaba da raguwa a cikin lokaci, ta hanyar FDA ta Amurka a watan Oktoba 2014 da EMA a cikin Janairu 2015. FDA ta ba da nintedanib esylate mai sauri-track. , Bita na fifiko, samfuran marayu, da nadi na ƙima.EMA kuma ta amince da ita a watan Nuwamba 2014 don maganin ciwon huhu mara ƙananan ƙwayoyin cuta a hade tare da docetaxel bayan layin farko na chemotherapy.